228 related articles for article (PubMed ID: 26931184)
21. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S
Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021
[TBL] [Abstract][Full Text] [Related]
22. Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study.
Roland CL; Ross MI; Hall CS; Laubacher B; Upshaw J; Anderson AE; Lucci A
Melanoma Res; 2015 Aug; 25(4):335-41. PubMed ID: 26011119
[TBL] [Abstract][Full Text] [Related]
23. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
24. Significance of 5-
Wakamatsu K; Fukushima S; Minagawa A; Omodaka T; Hida T; Hatta N; Takata M; Uhara H; Okuyama R; Ihn H
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936623
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T
Neoplasma; 2002; 49(2):121-5. PubMed ID: 12088105
[TBL] [Abstract][Full Text] [Related]
26. Circulating biomarkers in malignant melanoma.
Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
[TBL] [Abstract][Full Text] [Related]
27. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
28. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
29. The prognostic role of detection of circulating melanoma cells in the blood.
Dutcher JP
J Clin Oncol; 2003 Mar; 21(5):757-9. PubMed ID: 12610168
[No Abstract] [Full Text] [Related]
30. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.
Wang TS; Johnson TM; Cascade PN; Redman BG; Sondak VK; Schwartz JL
J Am Acad Dermatol; 2004 Sep; 51(3):399-405. PubMed ID: 15337983
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of multiple serum markers in advanced melanoma.
Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
[TBL] [Abstract][Full Text] [Related]
33. Circulating melanoma cells and survival in metastatic melanoma.
Rao C; Bui T; Connelly M; Doyle G; Karydis I; Middleton MR; Clack G; Malone M; Coumans FA; Terstappen LW
Int J Oncol; 2011 Mar; 38(3):755-60. PubMed ID: 21206975
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
Palmieri G; Ascierto PA; Perrone F; Satriano SM; Ottaiano A; Daponte A; Napolitano M; Caracò C; Mozzillo N; Melucci MT; Cossu A; Tanda F; Gallo C; Satriano RA; Castello G
J Clin Oncol; 2003 Mar; 21(5):767-73. PubMed ID: 12610172
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of melanin-related metabolites as markers of melanoma progression.
Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
[TBL] [Abstract][Full Text] [Related]
36. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma.
Gao D; Ma X
Panminerva Med; 2017 Dec; 59(4):332-337. PubMed ID: 27309261
[TBL] [Abstract][Full Text] [Related]
37. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance.
Nezos A; Lembessis P; Sourla A; Pissimissis N; Gogas H; Koutsilieris M
Clin Chem Lab Med; 2009; 47(1):1-11. PubMed ID: 19055471
[TBL] [Abstract][Full Text] [Related]
38. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma.
Hartleb J; Damm Y; Arndt R; Christophers E; Stockfleth E
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):31-42. PubMed ID: 10360420
[TBL] [Abstract][Full Text] [Related]
39. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity.
Fusi A; Berdel R; Havemann S; Nonnenmacher A; Keilholz U
Eur J Cancer; 2011 Sep; 47(13):1971-6. PubMed ID: 21570823
[TBL] [Abstract][Full Text] [Related]
40. [Serum markers for melanoma].
Ugurel S
Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
